
Pashtoon Kasi/LinkedIn
Jun 2, 2025, 16:15
Pashtoon Kasi Shares Results from LODESTAR Trial on Rucaparib in HRR-Mutated Solid Tumors
Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, shared a post on X:
“This is what excites me. Precision Oncology agnostic of tissue type. We enrolled patients with a variety of cancers to this 1st AGNOSTIC PARP trial. Long journey.
Finally over the finishing line.
BRCA, PALB2, RAD, BARD, and more.”
Title: LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes.
Authors: Sriram Anbil, Nicholas Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Kasi, Douglas Laux, Gary Schwartz, Geoffrey Shapiro, Kevin Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa Schrock, Shuoguo Wang, Ethan Sokol, Brennan Decker, Katherine Nathanson, Susan Domchek, Kim Reiss
Read the Full Abstract
More posts featuring Pashtoon Kasi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33
Jun 4, 2025, 15:56
Jun 4, 2025, 14:21
Jun 4, 2025, 13:42